Remove Containment Remove Genotoxicity Remove Genotype Remove Production
article thumbnail

Treatment of Metastatic Triple-Negative Breast Cancer

The Pharma Data

The MAA is now under accelerated review by the EMA, in recognition of the product being considered of major interest for public health and therapeutic innovation. SG contains a genotoxic component and can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. Embryo-Fetal Toxicity.

article thumbnail

TrodelvyĀ®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

The Pharma Data

The incidence of Grade 3-4 neutropenia in genotyped patients was 69% in patients homozygous for the UGT1A1*28, 48% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells.

HR 52